Soligenix Inc. (SNGX) shares were rising 13.87% to trade at $0.78 in pre-market at last check. Soligenix (SNGX) stock lost -0.72% to close Thursday’s session at $0.69. The stock volume remained 99333.0 shares, which was lower than the average daily volume of 0.47 million shares within the past 50 days.

Soligenix (SNGX) shares have fallen by -62.97% over the last 12 months, and they have moved down by -6.25% in the past week. Over the past three months, the stock has lost -2.28%, while over the past six months, it has shed -37.73%. Further, the company has a current market of $29.41 million and its outstanding shares stood at 42.87 million. SNGX stock is rising after sharing results from a clinical study.

What SNGX has shared?

Soligenix (SNGX) is a late-stage biopharmaceutical organization zeroed in on creating and commercializing items to treat uncommon infections where there is a neglected clinical need. SNGX’s Specialized BioTherapeutics business section is creating and advancing toward the likely commercialization of HyBryte (SGX301 or engineered hypericin) as a novel photodynamic treatment using safe noticeable light for the treatment of cutaneous T-cell lymphoma (CTCL).

Soligenix (SNGX) declared today the results of a sponsor immunization concentrate on utilizing CiVax (heat stable COVID-19 subunit antibody program) in non-human primates (NHPs).

• SNGX concentrate on showed a quick upgrade of killing neutralizer reactions to SARS-CoV-2, including against Delta and Omicron variations.
• The NHPs had been twofold inoculated with an adenovirus immunization for COVID-19 seven months beforehand.
• Before the organization of the promoter immunization, killing neutralizer levels against the first and Delta strains of SARS-CoV-2 were low, however perceptible, and were imperceptible for the Omicron strain.
• In no less than multi-week of getting supporter, killing immune response levels expanded as much as 27-overlap against the first and Delta strains.
• By three weeks this expanded up to 243-overlay.
• Defensive killing immunizer levels were additionally quickly raised against Omicron by one-week post-inoculation.
• These outcomes are reliable with the wide range of movement saw to date with CiVax on essential immunization, as depicted in an article as of late distributed by ACS Infectious Diseases.

Where this study could lead SNGX to?

As a result, Soligenix (SNGX) can develop an immunization against COVID-19, such as CiVax, which will be stronger at higher temperatures, leading to a faster solution to the global pandemic and reducing the spread of the virus. SNGX accepts that the stage not just can possibly support the current overall pandemic, however, may likewise help with the groundwork for future pandemics.